Decarbonization tech startup with Houston office scores $20M from United, Microsoft, and others

fresh funds

Among Dimensional Energy's funders are Microsoft and United. Photo via dimensionalenergy.com

Climatech company Dimensional Energy, which operates a Houston office, has scooped up $20 million in series A funding.

Founded in 2014, Ithaca, New York-based Dimensional Energy specializes in producing decarbonization technology, sustainable aviation fuel, and carbon emissions-derived fuels and materials. South Korea’s Envisioning Partners led the round, with participation from investors such as:

  • United Airlines’ Sustainable Flight Fund
  • Microsoft’s Climate Innovation Fund
  • RockCreek Group’s Smart Aviation Futures fund
  • DSC Investment
  • Delek US
  • Empire State Development
  • Climate Tech Circle

The company also says it’s working toward becoming a certified B Corporation. Businesses that achieve this certification seek to balance purpose and profit.

Dimensional Energy says the $20 million funding round positions it for “significant growth,” enabling it to:

  • Build the world’s first advanced power-to-liquid fuel plant and continue developing commercial power-to-liquid fuel plants.
  • Roll out the company’s initial B2B and B2C products, such as a fossil-free surf wax and a cruelty-free fat alternative for vegan food manufacturers.
  • Evolve the company’s proprietary reactor and catalyst technologies, which are being tested at its pilot plant in Tucson, Arizona.

“The world needs immediate and rapid decarbonization across all sectors, and Dimensional Energy shows great promise as a cleaner and lower-carbon aviation solution alongside reductions in industrial emissions,” Brandon Middaugh, senior director of Microsoft’s Climate Innovation Fund, says in a news release.

Dimensional Energy’s technology transforms carbon dioxide emissions into sustainable aviation fuel (SAF), renewable diesel, and synthetic paraffin that can be refined into more than 6,000 everyday products.

“Dimensional Energy particularly stood out to us for their differentiated technology, exceptional team, and significant progress to date towards producing SAF and other industrial products from CO2,” says Justin Heyman, managing director at RockCreek. “This technology can significantly reduce the environmental footprint of the airline industry.”

------

This article originally ran on EnergyCapital.

The Rice Alliance for Technology and Entrepreneurship handed out awards to the founders of the most promising companies that pitched. Photo courtesy of Slyworks Photography/Rice Alliance

Investors name most promising energy tech startups at annual Houston event

ones to watch

Nearly 100 energy tech startups pitched at the 19th annual Rice Alliance Energy Tech Venture Forum this week — and over a third of those companies are based in the Houston area.

At the conclusion of the event — which took place on Thursday, September 15, at Rice University, and included a day full of company pitches, panels, and thought leadership — 10 startups were deemed the most promising among their peers. The group was voted on by investors attending office hours ahead of the event.

The Rice Alliance for Technology and Entrepreneurship facilitated nearly 700 meetings between 70 investor groups and 90 ventures, according to the organization. The group of presenting companies included participants from Rice's Clean Energy Accelerator's first two cohorts.

Here are 10 of the energy tech industry's most promising companies — and the technology they are working on that's set to disrupt the status quo.

Arolytics

Based in Calgary and founded in 2018, Arolytics is a software company that specializes in emissions management, ESG performance, and regulatory compliance. The company's platform is able to save its users up to 40 percent of their associated measurement costs and emissions management.

Atargis Energy

Atargis Energy is based in Pueblo, Colorado, and is a a member of Rice's second cohort of its Clean Energy Accelerator. The company has developed a twin hydrofoil-based wave energy converter that creates electric power from ocean waves. The technology is paired with real-time sensors and machine learning to optimize power conversion.

Compact Membrane Systems

Based in Delaware, Compact Membrane Systems, is pioneering membrane systems for decarbonizing hard-to-abate chemical manufacturing and industrial carbon capturing. The technology has the potential to revolutionize the chemicals industry.

Dimensional Energy

Dimensional Energy, based in Ithaca, New York, is transforming carbon dioxide into sustainable aviation fuels and products at market competitive prices. The technology integrates carbon capture, electrolysis, and Fischer Tropsch synthesis.

Kanin Energy

Headquartered in Houston, Kanin Energy works with heavy Industry to turn their waste heat into a clean baseload power source. The platform also provides tools such as project development, financing, and operations.

Orbital Sidekick

Orbital Sidekick, based in San Francisco, is an intelligence and analytics company that specializes in remote detection of environmental hazards by way of hyperspectral satellites. The technology provides actionable insights for its customers.

Power to Hydrogen

Based in Columbus, Ohio, Power to Hydrogen has developed an AEM-based electrolysis technology that produces high pressure, high efficiency hydrogen at low cost via water and renewable energy.

Quino Energy

Another Clean Energy Accelerator Class 2 member, Quino Energy produces flow battery systems with over eight hours of energy storage. The batteries are cheaper than lithium-ion alternatives, as well as being safer and easier to scale.

STARS Technology

Based in Richland, Washington, STARS Technology Corp. is commercializing advanced micro-channel chemical process technology that originally was designed for NASA and the Department of Energy. The company's reactors and heat exchangers are compact, energy-efficient, and more.

Syzygy Plasmonics

Houston-based Syzygy Plasmonics is commercializing its light-reacting energy, which would greatly reduce carbon emissions in the chemical industry. The technology originated out of Rice University.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston digital health platform Koda lands strategic investment

money moves

Houston-based advance care planning platform Koda Health has added another investor to the lineup.

The company secured a strategic investment for an undisclosed amount from UPMC Enterprises, the commercialization arm of the University of Pittsburgh Medical Center. The funding is part of Koda's oversubscribed series A funding round that closed in October, according to a release.

"UPMC Enterprises’ investment is a meaningful signal, not just to Koda, but to the broader market," Dr. Desh Mohan, chief medical officer and co-founder of Koda Health, said in the news release. "It validates that health systems are ready to invest in infrastructure that makes advance care planning work the way it should: proactively, at scale, and with the human support that these conversations require. Having UPMC Enterprises as a strategic investor puts us in a unique position to prove what's possible."

Koda has raised $14 million to date, according to a representative from the company. Its series A round was led by Evidenced, with participation from Mudita Venture Partners, Techstars and the Texas Medical Center last year. At the time, the company said the funding would allow it to scale operations and expand engineering, clinical strategy and customer success. The company described the round as a "pivotal moment," as it had secured investments from influential leaders in the healthcare and venture capital space.

Koda Health, which was born out of the TMC's Biodesign Fellowship in 2020, saw major growth last year, as well, and now supports more than 1 million patients nationwide through partnerships with Cigna Healthcare, Privia Health, Guidehealth, Sentara, UPMC and Memorial Hermann Health System.

The company integrated its end-of-life care planning platform with Dallas-based Guidehealth in April 2025 and with Epic Systems in July 2025. It also won the 2025 Houston Innovation Award in the Health Tech Business category. Read more here.

UH med school gets $2M gift and more top Houston innovation news

Trending Topics

Editor's note: The top Houston innovation news of the month is full of fresh funding, with two Texas medical schools receiving major gifts — one of historic proportions. Below are the five most-read InnovationMap headlines from April 16-30, 2026.

UH med school granted $2M gift to offer student scholarships

A new scholarship endowment aims to support students in the University of Houston’s recently established medical school. The University of Houston’s Tilman J. Fertitta Family College of Medicine received a planned estate gift commitment estimated at $2.1 million to establish the Bob Diehl and Teresa Evans Diehl Scholarship Endowment. The scholarship will assist full-time medical students who demonstrate financial need and meet academic standards. Continue reading.

How Houston innovators played a role in the historic Artemis II splashdown

Research from Rice University played a critical role in the safe return of U.S. astronauts aboard NASA’s Artemis II mission this month. Rice mechanical engineer Tayfun E. Tezduyar and longtime collaborator Kenji Takizawa developed a key computational parachute fluid-structure interaction (FSI) analysis system that proved vital in NASA’s Orion capsule’s descent into the Pacific Ocean. The FSI system, originally developed in 2013 alongside NASA Johnson Space Center, was critical in Orion’s three-parachute design, which slowed the capsule as it returned to Earth, according to Rice. Continue reading.

Baylor scientist lands $2M grant to explore links between viruses and Alzheimer’s

A Baylor College of Medicine scientist will begin exploring the possible link between Alzheimer’s disease and viral infections thanks to a $2 million grant awarded in March. Dr. Ryan S. Dhindsa hypothesizes that Alzheimer’s may have some link to previous viral infections contracted by the patient. To study this intriguing possibility, the American Brain Foundation has gifted him the Cure One, Cure Many award in neuroinflammation. Continue reading.

New UT Austin med center, anchored by MD Anderson, gets historic gift

A donation announced April 21 breaks a major record at the University of Texas at Austin. Michael and Susan Dell are now UT Austin's first supporters to give $1 billion. In response, the university will create the UT Dell Campus for Advanced Research and the UT Dell Medical Center to "advance human health," per a press release. Continue reading.

Houston VC funding surged nearly 50% in Q1 2026, report says

Houston saw a jump in VC funding in Q1 2026, fueled by several major investments in clean energy startups. Image via Getty Images

First-quarter venture capital funding for Houston-area startups climbed nearly 50 percent compared to the same time last year, according to the PitchBook-NVCA Venture Monitor. In Q1 2026, Houston-area startups raised $532.3 million, a 49 percent jump from $320.2 million in Q1 2025, according to the PitchBook-NVCA Venture Monitor. However, the Q1 total fell 23 percent from the $671.05 million raised in Q4 2025. Continue reading.

New 'living pharmacy' biotech company launches out of Rice venture studio

fighting cancer

Rice University’s biotech venture studio RBL LLC has launched a new “living pharmacy” company, Duracyte, designed to make cancer treatment easier on patients.

Backed by an up to $45 million Advanced Research Projects Agency for Health (ARPA-H) award, Duracyte aims to commercialize implantable biohybrid pharmacy devices that are designed to produce therapeutic proteins inside the human body around the clock, replacing the need for regular injections and infusions for some cancer patients.

The company’s main platform is its Hybrid Advanced Molecular Manufacturing Regulator (HAMMR), a rechargeable, implantable device that can sense biological signals, monitor tumor environments and adjust therapeutic output in real time. HAMMR has wireless communication capabilities, which allow patients and clinicians to remotely monitor results through an app every five minutes and make changes to treatment plans without a hosptial visit. Additionally, the device can generate its own oxygen supply, which is key for the therapeutic cells’ survival.

“Biologic medicines such as monoclonal antibodies, cytokines and metabolic regulators already account for a significant share of modern therapeutics, but the way we deliver them today often requires frequent injections or infusions that can be demanding for patients and lead to inconsistent drug levels,” Daniel Anderson, MIT professor and co-founder of Duracyte, said in a news release. “Our vision is to enable a continuous, stable therapy by producing these medicines directly inside the body, which could improve treatment consistency, reduce side effects and ultimately transform how biologic therapies are delivered across many diseases.”

Duracyte’s first clinical trial is slated to begin by the end of 2026 and will focus on recurrent ovarian cancer. The Phase I study will build upon existing work on encapsulated cytokine pharmacy technology, and the company hopes that within a few years this treatment can reach clinical application.

The development of Duracyte is supported by ARPA-H's Targeted Hybrid Oncotherapeutic Regulation (THOR) project, which supports a multidisciplinary research consortium co-led by Omid Veiseh, a professor of bioengineering at Rice. The consortium also includes others at Rice, The University of Texas MD Anderson Cancer Center, Stanford University, Carnegie Mellon University, Northwestern University and the University of Houston, plus industry collaborators like Chicago-based CellTrans.

“What we are building is the culmination of years of progress in cell engineering, biomaterials and implantable device technology,” Veiseh added in the release. “By combining these advances with real-time sensing and adaptive drug delivery, we are working with the support of RBL to create a true ‘living pharmacy’ that can deliver continuous, precisely controlled biologic therapies and fundamentally change how these treatments reach patients.”

RBL launched in 2024 and is based out of Houston’s Texas Medical Center Helix Park. Duracyte is the third company launched by RBL, including Sentinel BioTherapeutics, a clinical-stage immunotherapy company developing localized cytokine therapies for solid tumors, and SteerBio, a regenerative medicine company targeting lymphedema.

“Duracyte exemplifies the kind of breakthrough that Houston’s ecosystem is built to produce,” Paul Wotton, managing partner of RBL LLC and co-founder of Duracyte, added in the release. “With world-class clinical infrastructure, exceptional engineering talent and initiatives like the Texas Biotech Task Force driving alignment across industry, investment and talent, this region is uniquely positioned to move the most ambitious ideas in medicine from concept to patient, faster than anywhere else.”

View All Listings